Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $13.4 million.

  • OptimizeRx's Cash & Equivalents rose 2104.06% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 2104.06%. This contributed to the annual value of $13.4 million for FY2024, which is 340.75% down from last year.
  • Latest data reveals that OptimizeRx reported Cash & Equivalents of $13.4 million as of FY2024, which was down 340.75% from $13.9 million recorded in FY2023.
  • Over the past 5 years, OptimizeRx's Cash & Equivalents peaked at $84.7 million during FY2021, and registered a low of $10.5 million during FY2020.
  • In the last 5 years, OptimizeRx's Cash & Equivalents had a median value of $13.9 million in 2023 and averaged $28.1 million.
  • In the last 5 years, OptimizeRx's Cash & Equivalents skyrocketed by 70520.66% in 2021 and then plummeted by 7849.6% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Cash & Equivalents stood at $10.5 million in 2020, then skyrocketed by 705.21% to $84.7 million in 2021, then crashed by 78.5% to $18.2 million in 2022, then decreased by 23.93% to $13.9 million in 2023, then decreased by 3.41% to $13.4 million in 2024.
  • Its last three reported values are $13.4 million in FY2024, $13.9 million for FY2023, and $18.2 million during FY2022.